Go to
current issue
-
Pembrolizumab or Placebo Plus Adjuvant Chemotherapy With or Without Radiotherapy For Newly Diagnosed, High-Risk Endometrial Cancer: Results in Mismatch Repair-Deficient Tumors J. Clin. Oncol. (IF 42.1) Pub Date : 2024 Brian M. Slomovitz, David Cibula, Weiguo Lv, Fırat Ortaç, Sakari Hietanen, Floor Backes, Akira Kikuchi, Domenica Lorusso, Anna Dańska-Bidzińska, Vanessa Samouëlian, Maria-Pilar Barretina-Ginesta, Christof Vulsteke, Chyong-Huey Lai, Bhavana Pothuri, Yu Zhang, Manuel Magallanes-Maciel, Amnon Amit, Valentina Guarneri, Flora Zagouri, Maria Bell, Julia Welz, Gemma Eminowicz, Martin Hruda, Lyndsay J. Willmott
Journal of Clinical Oncology, Volume 0, Issue ja, -Not available-.
-
DKN-01 in Combination With Tislelizumab and Chemotherapy as First-Line Therapy in Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: DisTinGuish J. Clin. Oncol. (IF 42.1) Pub Date : 2024 Samuel J. Klempner, Mohamad Bassam Sonbol, Zev A. Wainberg, Hope Elizabeth Uronis, Vi K. Chiu, Aaron James Scott, Syma Iqbal, Mohamedtaki Abdulaziz Tejani, Vincent Chung, Melissa C. Stilian, Mathis Thoma, Ying Zhang, Michael H. Kagey, Jason Baum, Cynthia A. Sirard, Rachel A. Altura, Jaffer A. Ajani
Journal of Clinical Oncology, Ahead of Print.
-
Omission of Radiotherapy in Primary Mediastinal B-Cell Lymphoma: IELSG37 Trial Results J. Clin. Oncol. (IF 42.1) Pub Date : 2024
Journal of Clinical Oncology, Ahead of Print.
-
End Point Surrogacy in First-Line Chronic Lymphocytic Leukemia J. Clin. Oncol. (IF 42.1) Pub Date : 2024 Florian Simon, Rudy Ligtvoet, Sandra Robrecht, Paula Cramer, Nadine Kutsch, Moritz Fürstenau, Valentin Goede, Julia von Tresckow, Petra Langerbeins, Anna-Maria Fink, Henriette Huber, Eugen Tausch, Christof Schneider, Clemens M. Wendtner, Matthias Ritgen, Martin Dreyling, Lothar Müller, Lutz Jacobasch, Werner J. Heinz, Ursula Vehling-Kaiser, Liliya Sivcheva, Sebastian Böttcher, Peter Dreger, Thomas
Journal of Clinical Oncology, Ahead of Print.
-
Adjuvant Nivolumab for Localized Renal Cell Carcinoma at High Risk of Recurrence After Nephrectomy: Part B of the Randomized, Placebo-Controlled, Phase III CheckMate 914 Trial J. Clin. Oncol. (IF 42.1) Pub Date : 2024 Robert J. Motzer, Axel Bex, Paul Russo, Yoshihiko Tomita, Hernan Javier Cutuli, Carlos Rojas, Marine Gross-Goupil, Giovanni Schinzari, Bohuslav Melichar, Philippe Barthélémy, Abraham Ruiz Garcia, Jeffrey Sosman, Marc-Oliver Grimm, Jeffrey C. Goh, Cristina Suarez, Christian K. Kollmannsberger, Suresh G. Nair, Brian M. Shuch, Jian Huang, Burcin Simsek, Julia Spiridigliozzi, Chung-Wei Lee, Maximiliano
Journal of Clinical Oncology, Ahead of Print.
-
Radiotherapy Versus Transoral Robotic Surgery for Oropharyngeal Squamous Cell Carcinoma: Final Results of the ORATOR Randomized Trial J. Clin. Oncol. (IF 42.1) Pub Date : 2024 Anthony C. Nichols, Julie Theurer, Eitan Prisman, Nancy Read, Eric Berthelet, Eric Tran, Kevin Fung, John R. de Almeida, Andrew Bayley, David P. Goldstein, Michael Hier, Khalil Sultanem, Keith Richardson, Alex Mlynarek, Suren Krishnan, Hien Le, John Yoo, S. Danielle MacNeil, Eric Winquist, J. Alex Hammond, Varagur Venkatesan, Sara Kuruvilla, Andrew Warner, Sylvia Mitchell, Jeff Chen, Stephanie Johnson-Obaseki
Journal of Clinical Oncology, Ahead of Print.
-
Navigating Hormone Therapy in Postmenopausal Women: Balancing Symptom Relief With Cancer Risk J. Clin. Oncol. (IF 42.1) Pub Date : 2024 Mali Barbi, Megan Gorman, Veena S. John
Journal of Clinical Oncology, Ahead of Print.
-
Methodological Considerations for Ensuring Robustness in Exercise and Breast Cancer Recurrence Studies J. Clin. Oncol. (IF 42.1) Pub Date : 2024 Sen Yang
Journal of Clinical Oncology, Ahead of Print.
-
Sex-Based Differences in Risk of Therapy-Related Myeloid Neoplasms J. Clin. Oncol. (IF 42.1) Pub Date : 2024 Melissa A. Richard, Chengcheng Yan, Yanjun Chen, Christopher J. Gibson, Rashi Kalra, Alysia Bosworth, David K. Crossman, Purnima Singh, Lindsey Hageman, Jianbo He, Saro H. Armenian, Julie Vose, Daniel J. Weisdorf, Benjamin L Ebert, Yutaka Yasui, Changde Cheng, Stephen J. Forman, Smita Bhatia, Ravi Bhatia
Journal of Clinical Oncology, Ahead of Print.
-
PEARL: A Phase Ib/II Biomarker Study of Adding Radiation Therapy to Pembrolizumab Before Neoadjuvant Chemotherapy in Human Epidermal Growth Factor Receptor 2–Negative Breast Cancer J. Clin. Oncol. (IF 42.1) Pub Date : 2024 Alice Y. Ho, Stephen Shiao, Samantha A. Kobald, Jonathan Chen, Dan G. Duda, Amy Ly, Veerle Bossuyt, Hae Lin Cho, Brittany Arnold, Simon Knott, Gaorav P. Gupta, Philomena McAndrew, Scott Karlan, Mourad Tighiouart, Alona Muzikansky, Reva Basho, Heather McArthur
Journal of Clinical Oncology, Ahead of Print.
-
Randomized Phase III SIERRA Trial of 131I-Apamistamab Before Allogeneic Hematopoietic Cell Transplantation Versus Conventional Care for Relapsed/Refractory AML J. Clin. Oncol. (IF 42.1) Pub Date : 2024 Boglarka Gyurkocza, Rajneesh Nath, Stuart Seropian, Hannah Choe, Mark R. Litzow, Camille Abboud, Nebu Koshy, Patrick Stiff, Benjamin Tomlinson, Sunil Abhyankar, James Foran, Parameswaran Hari, George Chen, Zaid Al-Kadhimi, Partow Kebriaei, Mitchell Sabloff, Johnnie J. Orozco, Katarzyna Jamieson, Margarida Silverman, Koen Van Besien, Michael Schuster, Arjun Datt Law, Karilyn Larkin, Neeta Pandit-Taskar
Journal of Clinical Oncology, Ahead of Print.
-
Breast Cancer Screening Interval: Effect on Rate of Late-Stage Disease at Diagnosis and Overall Survival J. Clin. Oncol. (IF 42.1) Pub Date : 2024-08-21 Margarita L. Zuley, Andriy I. Bandos, Stephen W. Duffy, Durwin Logue, Rohit Bhargava, Priscilla F. McAuliffe, Adam M. Brufsky, Robert M. Nishikawa
Purpose Controversy continues regarding the effect of screening mammography on breast cancer outcomes. We evaluated late-stage cancer rate and overall survival (OS) for different screening intervals using a real-world institutional research data mart. Methods Patients having both a cancer registry record of new breast cancer diagnosis and prediagnosis screening history between 2004 and 2019 were identified
-
Telisotuzumab Vedotin Monotherapy in Patients With Previously Treated c-Met Protein–Overexpressing Advanced Non-Squamous EGFR-Wildtype NSCLC in the Phase 2 LUMINOSITY Trial J. Clin. Oncol. (IF 42.1) Pub Date : 2024-06-06 D. Ross Camidge, Jair Bar, Hidehito Horinouchi, Jonathan Goldman, Fedor Moiseenko, Elena Filippova, Irfan Cicin, Tudor Ciuleanu, Nathalie Daaboul, Chunling Liu, Penelope Bradbury, Mor Moskovitz, Nuran Katgi, Pascale Tomasini, Alona Zer, Nicolas Girard, Kristof Cuppens, Ji-Youn Han, Shang-Yin Wu, Shobhit Baijal, Aaron S. Mansfield, Chih-Hsi Kuo, Kazumi Nishino, Se-Hoon Lee, David Planchard, Christina
Journal of Clinical Oncology, Ahead of Print.
-
Dose/Exposure Relationship of Exercise and Distant Recurrence in Primary Breast Cancer J. Clin. Oncol. (IF 42.1) Pub Date : 2024-06-05 Davide Soldato, Stefan Michiels, Julie Havas, Antonio Di Meglio, Martina Pagliuca, Maria Alice Franzoi, Barbara Pistilli, Neil M. Iyengar, Paul Cottu, Florence Lerebours, Charles Coutant, Aurélie Bertaut, Oliver Tredan, Laurence Vanlemmens, Christelle Jouannaud, Iona Hrab, Sibille Everhard, Anne-Laure Martin, Fabrice André, Ines Vaz-Luis, Lee W. Jones
Journal of Clinical Oncology, Ahead of Print.
-
Lorlatinib vs crizotinib in treatment-naïve patients with advanced ALK+ non-small cell lung cancer: 5-year progression-free survival and safety from the CROWN study. J. Clin. Oncol. (IF 42.1) Pub Date : 2024-06-05 Geoffrey Liu, Enriqueta Felip, Tony S. K. Mok, Ross Andrew Soo, Julien Mazieres, Alice Tsang Shaw, Filippo de Marinis, Yasushi Goto, Yi-Long Wu, Dong-Wan Kim, Jean-Francois Martini, Rossella Messina, Jolanda Paolini, Anna Polli, Despina Thomaidou, Francesca Toffalorio, Todd Michael Bauer
Journal of Clinical Oncology, Volume 42, Issue 17_suppl, Page LBA8503-LBA8503, June 2024.
-
Sacituzumab govitecan (SG) vs docetaxel (doc) in patients (pts) with metastatic non-small cell lung cancer (mNSCLC) previously treated with platinum (PT)-based chemotherapy (chemo) and PD(L)-1inhibitors (IO): Primary results from the phase 3 EVOKE-01 study. J. Clin. Oncol. (IF 42.1) Pub Date : 2024-06-05 Oscar Juan-Vidal, Giannis Socrates Mountzios, Enriqueta Felip, Niels Reinmuth, Filippo de Marinis, Nicolas Girard, Vipul M. Patel, Takayuki Takahama, Scott Peter Owen, Douglas Reznick, Firas Benyamine Badin, Irfan Cicin, Sabeen Fatima Mekan, Riddhi Patel, Eric Zhang, Divyadeep Karumanchi, Marina Chiara Garassino
Journal of Clinical Oncology, Volume 42, Issue 17_suppl, Page LBA8500-LBA8500, June 2024.
-
Multi-site randomized trial of a collaborative palliative and oncology care model for patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) receiving non-intensive therapy. J. Clin. Oncol. (IF 42.1) Pub Date : 2024-06-05 Alison Kavanaugh, Joseph A. Greer, Vicki Jackson, Jillian Gustin, Alice S. Mims, Albert Cook, Thomas William LeBlanc, Joanna Choe, Mathew Reynolds, Amir Tahmasb Fathi, Gabriela Hobbs, Andrew Mark Brunner, Jennifer S. Temel
Journal of Clinical Oncology, Volume 42, Issue 17_suppl, Page LBA6508-LBA6508, June 2024.
-
Longitudinal clinical performance of a novel tumor-naive minimal residual disease assay in patients with resected stage II and III colorectal cancer: A subset analysis from the GALAXY study in CIRCULATE-Japan. J. Clin. Oncol. (IF 42.1) Pub Date : 2024-05-29 Kristiyana Kaneva, Christine Lo, Farahnaz Islam, Seung Won Hyun, Daniel Neems, Jason Yamada-Hanff, Terri Driessen, Hala Boulos, Chithra Sangli, Richard Blidner, Hideaki Bando, Robert Tell, Daisuke Kotani, Kate Sasser, Halla Nimeiri, Eiji Oki, Takayuki Yoshino
Journal of Clinical Oncology, Volume 42, Issue 16_suppl, Page 3618-3618, June 2024.
-
Characterizing clinical trials for CAR T targeting solid tumors from 2018 to 2023: A systematic review. J. Clin. Oncol. (IF 42.1) Pub Date : 2024-05-29 Fathima Shehnaz Ayoobkhan, Zahra Mahmoudjafari, Muhammad Umair Mushtaq, Al-Ola A. Abdallah, Weijing Sun, Faiz Anwer, Gary C. Doolittle, Joseph McGuirk, Raed Moh'd Taiseer Al-Rajabi, Joaquina Celebre Baranda, Nausheen Ahmed
Journal of Clinical Oncology, Volume 42, Issue 16_suppl, Page e15080-e15080, June 2024.
-
Evaluation of concordance between blood-based and matched tissue molecular testing in a regional cancer center. J. Clin. Oncol. (IF 42.1) Pub Date : 2024-05-29 Carlos E Zuazo, Taylor Brodie, David R. Braxton, Burton Larry Eisenberg, Michael J. Demeure
Journal of Clinical Oncology, Volume 42, Issue 16_suppl, Page e15062-e15062, June 2024.
-
Blood metabolites–based MCTarg for multi-cancer screening and clinical diagnosis. J. Clin. Oncol. (IF 42.1) Pub Date : 2024-05-29 Xinping Xu, Chunyan Zeng, Bei Qing, Li Liu, Guodong Song, Shuqi Yu, Tianqi Shao, Qingyan Wei, He Wen, Junyuan Hu, Wei Zhang, Youxiang Chen, Zhenkun Xia
Journal of Clinical Oncology, Volume 42, Issue 16_suppl, Page e15028-e15028, June 2024.
-
Development of novel MUC1-C targeting antibody-drug conjugate for pancreatic cancer treatment. J. Clin. Oncol. (IF 42.1) Pub Date : 2024-05-29 Govind Panchamoorthy, Deepak Raina, Brian Lawney, Surender Kharbanda, Ravi Jasuja
Journal of Clinical Oncology, Volume 42, Issue 16_suppl, Page e15025-e15025, June 2024.
-
Preliminary results from a first-in-human trial of AMT-116, a topoisomerase I inhibitor containing antibody-drug conjugate (ADC), in patients with advanced solid tumors. J. Clin. Oncol. (IF 42.1) Pub Date : 2024-05-29 Ganessan Kichenadasse, John J. Park, Sagun Parakh, Gary Edward Richardson, Mark Voskoboynik, John D. Powderly, Zhengbo Song, Shutong Liu, Yaling Huang, Shu-Hui Liu, Xun Meng
Journal of Clinical Oncology, Volume 42, Issue 16_suppl, Page e15010-e15010, June 2024.
-
Clinicopathologic and genomic characteristics of patients with advanced ovarian, breast, and prostate cancer treated with poly (ADP-ribose) polymerase inhibitors (PARPi) in a real-world setting. J. Clin. Oncol. (IF 42.1) Pub Date : 2024-05-29 Teodora Kuzmanovic, Maedeh Zokaei Nikoo, Lesil Brihn, Vicky Konig, Tejuana Watson, Teana Austin, Lauren Bokovitz, Tapas Ranjan Behera, Gabriel Savage, Megan Kilbane, Elizabeth M. Azzato, Zheng Jin Tu, Wen Wee Ma, Roberto Vargas, Jacob Miller, Emrullah Yilmaz, Ying Ni
Journal of Clinical Oncology, Volume 42, Issue 16_suppl, Page 3159-3159, June 2024.
-
Total toxicity burden as a practical tool to quantify the overall severity of multiple adverse events in clinical trials. J. Clin. Oncol. (IF 42.1) Pub Date : 2024-05-29 Ruitao Lin, Pablo Alvarez-Ballesteros, Erick Campbell, Hung Le, Ecaterina Elena Dumbrava, Timothy A. Yap, David S. Hong, Funda Meric-Bernstam, Peter F. Thall, Jordi Rodon Ahnert, Berta Martin Cullell
Journal of Clinical Oncology, Volume 42, Issue 16_suppl, Page 3156-3156, June 2024.
-
Results of IMPACT 2, a randomized study evaluating molecular profiling and targeted agents in metastatic cancer at MD Anderson Cancer Center. J. Clin. Oncol. (IF 42.1) Pub Date : 2024-05-29 Siqing Fu, David S. Hong, Sarina A. Piha-Paul, Aung Naing, Jordi Rodon Ahnert, Timothy A. Yap, Daniel D. Karp, Ecaterina Elena Dumbrava, John Heymach, Jaffer A. Ajani, Carrie Cartwright, Jennifer Beck, Clark R. Andersen, Michael Kahle, David J. Vining, Jeffrey S. Ross, Calvin Y. Chao, Donald A. Berry, Funda Meric-Bernstam
Journal of Clinical Oncology, Volume 42, Issue 16_suppl, Page 3153-3153, June 2024.
-
Pertuzumab plus trastuzumab (P+T) in patients (pts) with solid tumors with ERBB2or ERBB3amplification (amp) or mutations (mut): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study. J. Clin. Oncol. (IF 42.1) Pub Date : 2024-05-29 Elie G. Dib, Michael Rothe, Pam K. Mangat, Elizabeth Garrett-Mayer, Eugene Ahn, Ajjai Shivaram Alva, Navid Hafez, Evthokia Hobbs, Mehmet Akce, Deepti Behl, Carmen Julia Calfa, Timothy Lewis Cannon, Meredith McKean, Ramya Thota, Allison Paige Watson, Kathleen J Yost, Abby Gregory, Susan Halabi, Richard L. Schilsky
Journal of Clinical Oncology, Volume 42, Issue 16_suppl, Page 3142-3142, June 2024.
-
Single cell characterization of persistent cells upon immunotherapy treatment in colorectal and endometrial tumors: The SERPENTINE trial. J. Clin. Oncol. (IF 42.1) Pub Date : 2024-05-29 Carmen García Durán, Paula Nieto, Juan Francisco Grau Béjar, Gerard Deuner, David García-Illescas, Ginevra Caratu, Lorena Fariñas-Madrid, Miren Berasategi, Marta Grzelak, Asaf Rotem, Juan Luis Melero, Patricia Casbas-Hernandez, Nick Borcherding, Juan Nieto, Alena Gros, Josep Tabernero, Ana Oaknin, Elena Elez, Holger Heyn
Journal of Clinical Oncology, Volume 42, Issue 16_suppl, Page 3139-3139, June 2024.
-
A phase 1 study evaluating the safety, pharmacokinetics, and efficacy of fadraciclib, an oral CDK2/9 inhibitor, in patients with advanced solid tumors and lymphoma. J. Clin. Oncol. (IF 42.1) Pub Date : 2024-05-29 Do-Youn Oh, Elena Garralda, Maria Vieito, Julius Huang, Sarina A. Piha-Paul
Journal of Clinical Oncology, Volume 42, Issue 16_suppl, Page 3125-3125, June 2024.
-
Updated study results of novel FAK/ALK/ROS1 inhibitor APG-2449 in patients (pts) with non-small-cell lung cancer (NSCLC) resistant to second-generation ALK inhibitors. J. Clin. Oncol. (IF 42.1) Pub Date : 2024-05-29 Hongyun Zhao, Jianhua Chen, Zhengbo Song, Yanqiu Zhao, Yubiao Guo, Gang Wu, Hua Yang, Xiaoqing Yu, Fangfang Gao, Ruiguang Zhang, Jian Fang, Xiaoyan Lin, GuangLin Liu, Chen Yang, Lichuang Men, Eric Liang, Dajun Yang, Li Zhang, Yifan Zhai
Journal of Clinical Oncology, Volume 42, Issue 16_suppl, Page 3124-3124, June 2024.
-
Results of a phase 1, dose-finding study of Debio 0123 as monotherapy in adult patients with advanced solid tumors: Safety, pharmacokinetic, and preliminary antitumor activity data. J. Clin. Oncol. (IF 42.1) Pub Date : 2024-05-29 Manish Sharma, Reinhard Dummer, Ilaria Colombo, Egle Ramelyte, Leigh Seamon, Drew W. Rasco, Victor Rodriguez Freixinos, Vito Dozio, Tri Tat, Noemie Luong, Aliaksandr Hurynovich, Mokhtar Omar, Sandrine Micallef, Anne Bellon, Esteban Rodrigo Imedio, Anastasios Stathis
Journal of Clinical Oncology, Volume 42, Issue 16_suppl, Page 3120-3120, June 2024.
-
Phase Ib trial of tasurgratinib (E7090) with or without endocrine therapies for patients (pts) with ER+, HER2− recurrent/metastatic breast cancer (BC) after receiving a CDK4/6 inhibitor. J. Clin. Oncol. (IF 42.1) Pub Date : 2024-05-29 Toshinari Yamashita, Takanori Ishida, Kan Yonemori, Hiroji Iwata, Akihiko Shimomura, Kenjiro Aogi, Kenichi Inoue, Toru Mukohara, Takahiro Nakayama, Hitomi Sakai, Shigehisa Kitano, Shingo Kobayashi, Takuya Nakada, Ippei Suzuki, Yohei Otake, Junji Tsurutani
Journal of Clinical Oncology, Volume 42, Issue 16_suppl, Page 3103-3103, June 2024.
-
A first-in-human trial of selective CDK7 inhibitor Q901, in patients with advanced solid tumors: Interim results of a phase I study (QRNT-009). J. Clin. Oncol. (IF 42.1) Pub Date : 2024-05-29 Anthony B. El-Khoueiry, Angela Tatiana Alistar, Hani M. Babiker, Devalingam Mahalingam, Minal A. Barve, Joohyuk Sohn, Mitesh J. Borad, Jae Cheol Lee, Jiye Ahn, Dayoung Lee, Jinho Choi, Jeongjun Kim, Dong-Hoon Yu, Seung-Joo Lee, Borami Jeon, Stefan Proniuk, Jaeseung Kim, Kiyean Nam
Journal of Clinical Oncology, Volume 42, Issue 16_suppl, Page 3078-3078, June 2024.
-
A pan-cancer analysis of SMARCA4 alterations and the unique clinicogenomic characteristics associated with SMARCA4 mutation types. J. Clin. Oncol. (IF 42.1) Pub Date : 2024-05-29 Matteo Repetto, Justin Jee, Jason C. Chang, Pier Selenica, Andrea Gazzo, Allison L. Richards, Mark Donoghue, Carol Aghajanian, Jorge S. Reis-Filho, Britta Weigelt, Alexander E. Drilon, Robin Guo
Journal of Clinical Oncology, Volume 42, Issue 16_suppl, Page 3073-3073, June 2024.
-
Utility of [18F]FDG PET/CT in predicting pathological complete response to neoadjuvant therapy in breast cancer: A prospective study. J. Clin. Oncol. (IF 42.1) Pub Date : 2024-05-29 Martina Sollini, Roberta Zanca, Paola Tiberio, Rita De Sanctis, Bethania Fernandes, Marcello Rodari, Arturo Chiti, Lidija Antunovic, Armando Santoro
Journal of Clinical Oncology, Volume 42, Issue 16_suppl, Page 3070-3070, June 2024.
-
Therapeutic implications of phosphoproteomics in molecular cancer diagnostics. J. Clin. Oncol. (IF 42.1) Pub Date : 2024-05-29 Julia Woortman, Cecilia Bang Jensen, Amirhossein Sakhteman, Maria-Veronica Teleanu, Peter Horak, Simon Kreutzfeldt, Barbara Hutter, Jennifer Huellein, Moritz Resch, Christoph Stange, Chien-Yun Lee, Olaf Witt, David T.W. Jones, Daniel Hübschmann, Stefan M. Pfister, Wilko Weichert, Matthew The, Stefan Froehling, Bernhard Kuster
Journal of Clinical Oncology, Volume 42, Issue 16_suppl, Page 3068-3068, June 2024.
-
Relationship between dynamic changes in circulating tumor fraction and real-world imaging with real-world survival in patients with solid tumors treated with immunotherapy. J. Clin. Oncol. (IF 42.1) Pub Date : 2024-05-29 Akash Mitra, John Guittar, Ryan D. Gentzler, Regina M. Schwind, Adam Joseph Dugan, Yan Liu, Seung Won Hyun, Michelle M. Stein, Kate Sasser, Rotem Ben-Shachar, Halla Nimeiri, Jyoti D. Patel, Aadel A Chaudhuri
Journal of Clinical Oncology, Volume 42, Issue 16_suppl, Page 3046-3046, June 2024.
-
High-sensitive multi-cancers early detection for 8 cancer types by cell-free DNA targeted methylation sequencing: A retrospective cohort study. J. Clin. Oncol. (IF 42.1) Pub Date : 2024-05-29 Pansong Li, Wei Wei, Yong-Bin Lin, Hong Yang, Han Yang, Kong-Jia Luo, Xiaoman Hu, Haibo Qiu, Shu-Qiang Yuan, Yuan-fang Li, Xiao-Jun Lin, Bo-kang Cui, Li Xu, Rong-Xin Zhang, Wenhua Fan, Chunyan Lan, Ting Wan, Qi-hua Zhang, Rui-Hua Xu
Journal of Clinical Oncology, Volume 42, Issue 16_suppl, Page 3043-3043, June 2024.
-
Pooled safety analysis of sacituzumab govitecan (SG) in multiple solid tumor types. J. Clin. Oncol. (IF 42.1) Pub Date : 2024-05-29 Sara M. Tolaney, Aditya Bardia, Javier Cortes, Frederik Marmé, Peter Schmid, Lisa A. Carey, Sibylle Loibl, Kevin Kalinsky, Joyce O'Shaughnessy, Sara A. Hurvitz, Theresa Valdez, Ya Meng, Wendy Verret, Scott T. Tagawa
Journal of Clinical Oncology, Volume 42, Issue 16_suppl, Page 3029-3029, June 2024.
-
First-in-human phase I clinical trial of RSO-021, a first-in class covalent inhibitor of mitochondrial peroxiredoxin 3 (PRX3), in patients with malignant pleural effusion due to mesothelioma and other advanced solid tumors (MITOPE). J. Clin. Oncol. (IF 42.1) Pub Date : 2024-05-29 Sean Dulloo, Simon Lord, Fiona Thistlethwaite, Kevin G Blyth, Peter Wojciech Szlosarek, Nick Maskell, Sanjay Popat, Avinash Aujayeb, Burak Y Aktas, Sohail Rooman Javed, Julio Herrero Colomina, Brian Cunniff, Jarrett Duncan, Philippa Graham, Alice Susannah Bexon, George N Naumov, James F. Spicer
Journal of Clinical Oncology, Volume 42, Issue 16_suppl, Page 3019-3019, June 2024.
-
Updated safety and efficacy data of combined KRAS G12C inhibitor (glecirasib, JAB-21822) and SHP2 inhibitor (JAB-3312) in patients with KRAS p.G12C mutated solid tumors. J. Clin. Oncol. (IF 42.1) Pub Date : 2024-05-29 Jian Fang, Yan Yu, Qian Chu, Xiaoyan Li, Jiayan Chen, Zhe Liu, Li Zhang, Lin Wu, Wu Zhuang, XingYa Li, Yanqiu Zhao, Ligang Xing, Lian Liu, Chunmei Bai, Xiaorong Dong, Qibin Song, Pinghua Pan, Xuefeng Fang, Jie Wang
Journal of Clinical Oncology, Volume 42, Issue 16_suppl, Page 3008-3008, June 2024.
-
First-in-human phase I trial of the oral first-in-class ubiquitin specific peptidase 1 (USP1) inhibitor KSQ-4279 (KSQi), given as single agent (SA) and in combination with olaparib (OLA) or carboplatin (CARBO) in patients (pts) with advanced solid tumors, enriched for deleterious homologous recombination repair (HRR) mutations. J. Clin. Oncol. (IF 42.1) Pub Date : 2024-05-29 Nehal J. Lakhani, Amita Patnaik, Elizabeth Katherine Lee, Martin Gutierrez, Kathleen N. Moore, Benedito A. Carneiro, John L. Hays, Marilyn Huang, Patricia LoRusso, Andrew Wylie, Louise Cadzow, Matthew Goulet, Erica Tobin, Oliver Krieter, Daniela Schmid, Sophia M. Blake, Max Dieterich, Candice Jamois, Patricia M. Harris
Journal of Clinical Oncology, Volume 42, Issue 16_suppl, Page 3005-3005, June 2024.
-
FusionVAC22_01: A phase I clinical trial evaluating a DNAJB1-PRKACA fusion transcript-based peptide vaccine combined with immune checkpoint inhibition for fibrolamellar hepatocellular carcinoma and other tumor entities carrying the oncogenic driver fusion. J. Clin. Oncol. (IF 42.1) Pub Date : 2024-05-29 Michael Bitzer, Christopher Hackenbruch, Jens Bauer, Yacine Maringer, Annika Nelde, Helmut R. Salih, Juliane S. Walz
Journal of Clinical Oncology, Volume 42, Issue 16_suppl, Page TPS2702-TPS2702, June 2024.
-
EVEREST-1: A seamless phase 1/2 study of A2B530, a carcinoembryonic antigen (CEA) logic-gated Tmod CAR T-cell therapy, in patients with solid tumors associated with CEA expression also exhibiting human leukocyte antigen (HLA)-A*02 loss of heterozygosity (LOH). J. Clin. Oncol. (IF 42.1) Pub Date : 2024-05-29 Diane M. Simeone, Caleb Joshua Smith, Theodore H Welling, Kedar Kirtane, Patrick Grierson, Maria Pia Morelli, J. Randolph Hecht, Sandip Pravin Patel, Frederick L. Locke, Wen-Kai Weng, Marwan Fakih, Judy G. Vong, Kirstin B. Liechty, Eric Wai-Choi Ng, John Sutton Welch, Marcela Valderrama Maus, David G. Maloney, William Y. Go, Salman Rafi Punekar
Journal of Clinical Oncology, Volume 42, Issue 16_suppl, Page TPS2698-TPS2698, June 2024.
-
DUET-01: A first-in-human, phase 1/2 study of BOXR1030 in patients with advanced glypican-3-positive solid tumors. J. Clin. Oncol. (IF 42.1) Pub Date : 2024-05-29 Jonathan Robert Thompson, Amy Jensen-Smith, Ann Ranger, Ping Fan, Stanislav Katina, Pauline Duhard, Andrew Scott Paulson
Journal of Clinical Oncology, Volume 42, Issue 16_suppl, Page TPS2681-TPS2681, June 2024.
-
A phase 1 trial of TSC-100 and TSC-101, engineered T cell therapies that target minor histocompatibility antigens to eliminate residual disease after hematopoietic cell transplantation. J. Clin. Oncol. (IF 42.1) Pub Date : 2024-05-29 Alla Keyzner, Hyung C. Suh, Uday R. Popat, Saar Gill, Yi-Bin Albert Chen, Melhem M. Solh, Lohith Gowda, Erica Buonomo, Yun Wang, Jim Murray, Gavin MacBeath, Debora Barton, Shrikanta Chattopadhyay, Ran Reshef
Journal of Clinical Oncology, Volume 42, Issue 16_suppl, Page TPS2678-TPS2678, June 2024.
-
Effect of a novel anti-PD-1-proIL-2 bifunctional fusion protein on potent anti-tumor activity via PD-1 checkpoint inhibition and conditional IL-2R agonism. J. Clin. Oncol. (IF 42.1) Pub Date : 2024-05-29 Zijuan Li, Feifei Zhang, Ze Zhang
Journal of Clinical Oncology, Volume 42, Issue 16_suppl, Page e14697-e14697, June 2024.
-
Incidence of brain metastases within the VA Healthcare System. J. Clin. Oncol. (IF 42.1) Pub Date : 2024-05-29 Joseph Kamel Salama, Matthew J. Boyer
Journal of Clinical Oncology, Volume 42, Issue 16_suppl, Page e14691-e14691, June 2024.
-
Intravesical local administration of pembrolizumab for treatment of bladder cancer: A novel strategy to minimize toxicity. J. Clin. Oncol. (IF 42.1) Pub Date : 2024-05-29 Anirban B. Ganguly, Jason Hafron, Jonathan Kaufman, Michael Chancellor
Journal of Clinical Oncology, Volume 42, Issue 16_suppl, Page e14687-e14687, June 2024.
-
Integrated analysis of two phase 2 trials of nivolumab in metastatic rare solid cancer with dMMR or pMMR (MASTER KEY sub-studies: ROCK and ROLL trial). J. Clin. Oncol. (IF 42.1) Pub Date : 2024-05-29 Hitomi Sumiyoshi Okuma, Kenji Tsuchihashi, Ryunosuke Machida, Ryo Sadachi, Akihiro Hirakawa, Masahisa Kamikura, Kenta Anjo, Shigeki Sekine, Natsuko Tsuda Okita, Kenichi Nakamura, Kan Yonemori
Journal of Clinical Oncology, Volume 42, Issue 16_suppl, Page e14603-e14603, June 2024.
-
First-in-human phase I/II safety and preliminary efficacy of PM1032, a bispecific antibody targeting CLDN18.2 and 4-1BB, in patients with advanced solid tumors. J. Clin. Oncol. (IF 42.1) Pub Date : 2024-05-29 Lihua Wu, Yong Li, Jinhua Wen, Junli Xue, Zhuoyi Wang, Pu Li, Wei Zhao, Jingfeng Liu, Xi Rao, Qun Li, Liqiong Xue, Xiaoxiao Ge, Fengjuan Lin, Wenbo Tang, Jiuli Zhou
Journal of Clinical Oncology, Volume 42, Issue 16_suppl, Page 2662-2662, June 2024.
-
Exploring the diagnostic potential of cerebrospinal fluid (CSF) IL-10:IL-6 ratio in patients with primary central nervous system lymphoma (PCNSL). J. Clin. Oncol. (IF 42.1) Pub Date : 2024-05-29 Aastha Takkar Kapila, Gaurav Prakash, Vivek Lal, Vishali Gupta, Ranjana Walker Minz, karthik Vinay Mahesh
Journal of Clinical Oncology, Volume 42, Issue 16_suppl, Page e14041-e14041, June 2024.
-
Exploratory phase I study of HF1K16 for the treatment of patients with refractory/recurrent advanced glioma: Preliminary efficacy and mechanism as a monotherapy. J. Clin. Oncol. (IF 42.1) Pub Date : 2024-05-29 Anjie Zheng, Yuhong Xu, Xiaochen Zhang, Jinsong Wu
Journal of Clinical Oncology, Volume 42, Issue 16_suppl, Page e14030-e14030, June 2024.
-
Initial results from phase I trial of a novel oncolytic adenovirus Ad-TD-nsIL12 in recurrent glioblastoma connecting to ventricular system. J. Clin. Oncol. (IF 42.1) Pub Date : 2024-05-29 Weihai Ning, Yuduo Guo, Shenglun Li, Dixiang Song, Deshan Liu, Lixin Ma, Yujia Chen, Chao Zhao, Jiacheng Xu, Yanming Qu, Haoran Wang, Chunyu Gu, Mingshan Zhang, Yaohe Wang, Louisa Chard Dunmall, Shengdian Wang, Hongwei Zhang
Journal of Clinical Oncology, Volume 42, Issue 16_suppl, Page 2057-2057, June 2024.
-
Efficacy of intrathecal delivery of peptide-pulsed type 1 conventional dendritic cell vaccine for the treatment of breast cancer-associated leptomeningeal disease in preclinical models. J. Clin. Oncol. (IF 42.1) Pub Date : 2024-05-29 Colin Snyder, Zhihua Chen, Pawel Kalinski, Brian J. Czerniecki, Peter A. J. Forsyth
Journal of Clinical Oncology, Volume 42, Issue 16_suppl, Page 2030-2030, June 2024.
-
Genomic biomarkers of CNS-specific outcomes in patients with breast cancer brain metastases. J. Clin. Oncol. (IF 42.1) Pub Date : 2024-05-29 Jordan Eichholz, Lillian A Boe, Anton Safonov, Deborah Ruth Smith, Emanuela Ferraro, Junchao Shen, Brandon S. Imber, Yao Yu, Yoshiya Yamada, Emily Miao, Nelson S. Moss, Jessica Wilcox, Henry S. Walch, Walid Khaled Chatila, Nikolaus Schultz, Pedram Razavi, Luke R. G. Pike
Journal of Clinical Oncology, Volume 42, Issue 16_suppl, Page 2028-2028, June 2024.
-
Stereotactic radiosurgery in patients with small cell lung cancer and 1-10 brain metastases: A multi-institutional, phase II, prospective clinical trial. J. Clin. Oncol. (IF 42.1) Pub Date : 2024-05-29 Wenya Linda Bi, Paul J. Catalano, Fallon Chipidza, Daphne A. Haas-Kogan, Lauren Hertan, David E. Kozono, Monica Krishnan, Raymond H. Mak, Itai Pashtan, Luke Peng, Jack Qian, Rifaquat Rahman, Ivy Ricca, Jacob Sands, Ron Y. Shiloh, Kee-Young Shin, Shyam Kumar Tanguturi
Journal of Clinical Oncology, Volume 42, Issue 16_suppl, Page 2020-2020, June 2024.
-
Evaluation of VAL-083 in GBM AGILE, a phase 3 registration platform trial for newly diagnosed and recurrent glioblastoma. J. Clin. Oncol. (IF 42.1) Pub Date : 2024-05-29 Timothy Francis Cloughesy, Donald A. Berry, Meredith Becker Buxton, Howard Colman, Benjamin M. Ellingson, Gary B. Gordon, Andrew B. Lassman, Michael Lim, Ingo K. Mellinghoff, Erik P. Sulman, Michael Weller, Patrick Y. Wen, Emma Maria Viktoria Hyddmark, Tom Mikkelsen, Scott Peter Owen, Warren P. Mason, Jan Drappatz, Nicholas Alfred Blondin, James R. Perry
Journal of Clinical Oncology, Volume 42, Issue 16_suppl, Page 2005-2005, June 2024.
-
Genetic testing in cancer care: An assessment of current practice in Africa. J. Clin. Oncol. (IF 42.1) Pub Date : 2024-05-29 Katy Graef, Abba Aji Mallum, Aishat Oladipo, Fatoumata Ibrahim, Heng Li, Joerg Lehmann, Kavuma Awusi, Luca Incrocci, M. Saiful Huq, Marueen Bilinga Tendwa, Rohini Bhatia, Samuel Olaolu Adeneye, Solomon Kibudde, Stephen Avery, Thokozani Mkhize, Twalib Athumani Ngoma, Wil Ngwa, William Swanson, Adedayo Joseph
Journal of Clinical Oncology, Volume 42, Issue 16_suppl, Page e13784-e13784, June 2024.
-
Incidence of mortality in vulnerable and non-vulnerable older patients with cancer. J. Clin. Oncol. (IF 42.1) Pub Date : 2024-05-29 David Hernandez Barajas, Omar Alejandro Zayas Villanueva, Estefania Elizabeth Abundis Márquez, Elias Román Urdiales Hidalgo
Journal of Clinical Oncology, Volume 42, Issue 16_suppl, Page e13775-e13775, June 2024.
更新日期：2024-11-05
Copyright © 2014-2024 北京衮雪科技有限公司 All Rights Reserved
京ICP备11026495号-2
京公网安备 11010802027423号
京公网安备 11010802027423号